What Happened?
Boston, MA-based Wave-Life-Sciences Appointed Paul Bolno as Chief Executive Officer
About the Company
Wave Life Sciences is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering exceptional treatment options for patients. Given the unique versatility of its chemistry platform, WAVE`s pipeline will span multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi.
About the Person
Dr. Bolno brings WAVE Life Sciences over 15 years of scientific and strategic leadership. Prior to joining as President and Chief Executive Officer, he was Vice President, Worldwide Business Development – Head of Asia BD and Investments, as well as Head of Global Neuroscience BD, at GlaxoSmithKline. He also served as a Director of Glaxo Welcome Manufacturing, Pte Ltd. in Singapore. Dr. Bolno joined GSK as Vice President, Business Development for the Oncology Business Unit, where he helped establish GSK`s global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GSK, he served as Director of Research at Two River LLC, a health care private equity firm. Dr. Bolno earned a medical degree from MCP-Hahnemann School of Medicine and an M.B.A. from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine.
Info Source
Press Release
Short Profile